Bernstein has turned bullish on India’s healthcare space and has identified Zydus Lifesciences as its top pick with a target price of ₹1,457, implying nearly 40% upside from current levels. The bullish stance comes at a time when the company is aggressively expanding in specialty drugs, strengthening its global presence and rewarding shareholders through a large buyback announcement.
Formerly known as Cadila Healthcare, Zydus Lifesciences is among India’s leading pharmaceutical companies with a strong presence across generics, specialty medicines, vaccines, biologics and consumer wellness products. The company also owns a 57.59% stake in Zydus Wellness, which houses popular brands in the health and nutrition segment. Over the years, Zydus has built a diversified business model spanning India, the US and several international markets.
The company currently commands a market capitalization of nearly ₹1.04 lakh crore, placing it among the biggest pharmaceutical players in India. Promoters hold a strong 75% stake, reflecting high confidence in the long-term prospects of the business. Domestic Institutional Investors own about 11.2% while Foreign Institutional Investors hold 6.95%.
One of the biggest triggers for the stock recently has been the company’s ₹1,100 crore buyback announcement. Zydus plans to repurchase shares at ₹1,150 apiece through the tender route, offering investors a premium over prevailing market prices. The move is widely being interpreted as management’s confidence in the company’s future earnings visibility and cash generation capabilities.
Financially, Zydus Lifesciences has been delivering strong numbers. The company reported a 9% year-on-year rise in Q4 FY26 consolidated net profit to ₹1,272.5 crore. Investors cheered the earnings performance, pushing the stock to fresh 52-week highs after results were announced.
The company’s return ratios also remain healthy, with Return on Equity (RoE) standing near 21%, indicating efficient capital allocation and robust profitability. Zydus has also maintained a relatively comfortable balance sheet compared to many peers, enabling it to pursue acquisitions and growth opportunities without stretching finances excessively.
A major reason brokerages are turning optimistic is Zydus’ increasing focus on high-value specialty therapies and complex products. The company recently announced the acquisition of US-based oncology player Assertio Holdings for $166 million to strengthen its cancer portfolio and US presence.
Management has also indicated that it will continue exploring acquisitions in specialty and rare disease segments, areas that generally command higher margins and stronger entry barriers compared to traditional generics.
Apart from its core pharma business, Zydus is gaining attention for its work in semaglutide-based diabetes and obesity therapies, oncology biosimilars and consumer wellness products. Market participants believe these segments could become major growth engines over the next few years. Retail investor discussions on forums such as Reddit have also highlighted optimism around the company’s semaglutide opportunity, oncology pipeline and improving international business momentum.
Bernstein believes the broader Indian pharma sector is entering a favourable phase supported by strong domestic demand, improving global competitiveness and structural tailwinds in healthcare. Within this space, Zydus stands out due to its diversified product portfolio, strong balance sheet, healthy return ratios and ambitious expansion plans.
While the stock has already seen a sharp run-up recently, the buyback, strong promoter holding, healthy financial performance and expanding specialty pipeline suggest that institutional investors continue to see long-term value in the company.